The OX40/OX40L Axis Promotes Th2 Activity and Impairs Regulatory T Cell Function in Atopic Dermatitis - PubMed
4 days ago
- #OX40/OX40L
- #Tregs
- #Atopic Dermatitis
- Monoclonal antibodies targeting the OX40/OX40L axis show promise in treating atopic dermatitis (AD).
- OX40/OX40L enhances effector T cell survival and inhibits regulatory T cell (Treg) function in inflammatory diseases.
- Study evaluates OX40 and OX40L expression in skin and blood of AD patients to understand inflammation mechanisms.
- Increased OX40+ and OX40L+ cells found in AD skin lesions compared to healthy controls.
- OX40 expression is upregulated in circulating CLA+CD4+ T cells and CLA+ Tregs in AD patients.
- OX40+CLA+CD4+ Tregs correlate with disease severity (SCORAD).
- OX40/OX40L axis maintains Th2 phenotype in effector CD4+ T cells and reduces IL-10 production by Tregs.
- Interaction between OX40L-expressing cells and T cells in skin promotes inflammation by impairing Treg function.